关注
Jesse Boumelha
Jesse Boumelha
在 mssm.edu 的电子邮件经过验证
标题
引用次数
引用次数
年份
Lung adenocarcinoma promotion by air pollutants
W Hill, EL Lim, CE Weeden, C Lee, M Augustine, K Chen, FC Kuan, ...
Nature 616 (7955), 159-167, 2023
2732023
Antibodies against endogenous retroviruses promote lung cancer immunotherapy
KW Ng, J Boumelha, KSS Enfield, J Almagro, H Cha, O Pich, T Karasaki, ...
Nature 616 (7957), 563-573, 2023
972023
Therapeutic KRASG12C inhibition drives effective interferon-mediated antitumor immunity in immunogenic lung cancers
E Mugarza, F van Maldegem, J Boumelha, C Moore, S Rana, ...
Science advances 8 (29), eabm8780, 2022
652022
Preclinical testing of an Atr inhibitor demonstrates improved response to standard therapies for esophageal cancer
KB Leszczynska, G Dobrynin, RE Leslie, J Ient, AJ Boumelha, JM Senra, ...
Radiotherapy and Oncology 121 (2), 232-238, 2016
472016
An immunogenic model of KRAS-mutant lung cancer enables evaluation of targeted therapy and immunotherapy combinations
J Boumelha, S de Carné Trécesson, EK Law, P Romero-Clavijo, ...
Cancer research 82 (19), 3435-3448, 2022
332022
The role of APOBEC3B in lung tumor evolution and targeted cancer therapy resistance
DR Caswell, P Gui, MK Mayekar, EK Law, O Pich, C Bailey, J Boumelha, ...
Nature Genetics 56 (1), 60-73, 2024
222024
Facts and hopes on RAS inhibitors and cancer immunotherapy
J Boumelha, M Molina-Arcas, J Downward
Clinical Cancer Research 29 (24), 5012-5020, 2023
42023
CRISPR–Cas9 Screening Identifies KRAS-Induced COX2 as a Driver of Immunotherapy Resistance in Lung Cancer
J Boumelha, A de Castro, N Bah, H Cha, S de Carné Trécesson, S Rana, ...
Cancer Research 84 (14), 2231-2246, 2024
12024
系统目前无法执行此操作,请稍后再试。
文章 1–8